Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

The sterile fill market isn't monolithic; it's segmented by manufacturing type. High-volume, low-mix products like GLP-1s require different CDMO capabilities than high-mix, lower-volume biologics. The latter demands deep expertise in tech transfer and new product launches, a distinct skill set from routine, high-scale production.

While tools like AI and robotics are transformative, a deep understanding of core principles like microbial physiology, mass transfer, and reaction kinetics remains essential. Technology augments, but does not replace, the critical thinking required to design robust experiments and interpret data.

The most common failure in automation is focusing on the robot or software. True success is determined by deeply understanding and codifying the entire process, including its environment and inherent variabilities. Getting the requirements right is the core challenge; the technology itself is secondary.

The standard practice is to optimize for productivity (titer) first, then correct for quality (glycosylation) later. This is reactive and inefficient. Successful teams integrate glycan analysis into their very first screening experiments, making informed, real-time trade-offs between productivity and quality attributes.

A common error is screening strains or media in a simple batch mode when the final process will be fed-batch. This mismatch leads to incorrect candidate ranking and selection, forcing teams to restart the development process once the error becomes apparent during scale-up.

The primary value of AI in bioprocessing is not just automating tasks, but analyzing process data to predict outcomes. This requires a fundamental shift in capital equipment design, focusing on integrating more sensors and methods to collect far more granular data than is standard today.

The software-centric Minimum Viable Product (MVP) model is ill-suited for hardware. Instead of aiming for a 'viable' product, focus on a 'testable' one. This allows for controlled pilot deployments to gather real-world data and iterate before committing to expensive, hard-to-change physical designs.

In early microbial cultivation R&D, focusing on whether a system is 'stirred or shaken' is a distraction. The most critical parameter for success is the amount of oxygen introduced (KLa and oxygen transfer rate), not the mechanical method of delivery.